Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM
NCT02429258Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02429258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429258.